Silgan Dispensing, a global expert in the design, development and distribution of engineered pumps and sprayers in the pharmaceutical market, has announced the launch of the Gemini BE Nasal Pump.
Developed with Silgan Dispensing’s Bioequivalence (BE) Program, the Gemini BE Nasal Pump is adaptable to match specific formulations for a "perfect" performance fit. With an extensive five-stage custom process, Gemini allows for customisability with over 40 different spray configurations.
Additional benefits of the Gemini BE Nasal Pump include:
- Cleanroom, pharma-grade, and ISO-certified production
- High-dosing accuracy
- Low strokes to prime
- Capability to match existing reference listed drug (RLD) devices across a range of formulations
- Ability to modify spray characteristics like DSD, plume geometry, and spray pattern
“Bioequivalence testing helps our customers overcome regulatory and technical barriers that have previously slowed product commercialisation,” said Allan Houston, vice president sales & marketing, healthcare at Silgan Dispensing. “The Gemini BE Nasal Pump showcases our BE Program and Silgan Dispensing’s ability to deliver expedited nasal devices that fit our customers’ needs as a replacement or secondary supply chain option.”
Silgan Dispensing’s BE Program is aligned with U.S. FDA and EU methods. Additionally, the BE Program is supported by Silgan Dispensing’s regulatory team, utilising the company’s Nasal Spray Testing cGMP lab and equipment, and partners with accredited, external cGMP lab testing services and CMOs for nasal products.